Anakinra Prophylaxis Produces Lower Toxicities for Patients with Multiple MyelomaJuly 9th 2021
Anakinra prophylaxis was associated with lower incidences of ≥2 grade cytokine release syndrome and no adverse effects on the incidence of neurological events in patients with multiple myeloma.
Addressing Production and Logistic Challenges in Cell TherapyJuly 2nd 2021
“We've had to develop a unique process and a unique cryo buffer that allows us to freeze natural killer cells and recover greater than 90% of those cells. So, the new GDA-201 cryo-preserved is now going to be an off-the-shelf product and we're going to reinstitute a multicenter study in lymphoma to include both histologies of follicular lymphoma and diffuse large B cell lymphoma.”
Patients with Blood Cancer and COVID-19 Fare Better with Convalescent Plasma TreatmentJuly 1st 2021
A retrospective cohort study found that convalescent plasma treatment resulted in a meaningful improvement in the 30-day mortality rate for patients with hematologic cancer and COVID-19.
Omidubicel May Be a Potential Alternative to Bone Marrow TransplantJune 30th 2021
“So, what we’ve done is develop a technique, using the NAM technology, to expand those stem cells, so we can make 50 to 100-fold more stem cells, with higher reliability, and manufacture those cells for patients in need of a bone marrow transplant”
Early Trial Suggests that Targeting CLL1-Postive Cells is Effective in Treating Pediatric AMLJune 26th 2021
An early trial evaluated Anti-C-type lectin-like molecule-1 (CLL-1)-based CAR T cells for its safety and efficacy in improving the symptoms of pediatric patients with acute myeloid leukemia (AML).
FDA Approves Avapritinib for Rare Blood DiseaseJune 16th 2021
The FDA approved avapritinib (Ayvakit) for the treatment of adults with advanced systemic mastocytosis (AdvSM), including those with mast cell leukemia (MCL), aggressive systemic mastocytosism (ASM), or systemic mastocytosis with an associated hematological neoplasm (SM-AHN).
Discrepancies Exist Between Actual Care and Trial-Based Recommendations in MCLJune 14th 2021
A presentation at the European Hematology Association 2021 Virtual Congress demonstrated that discrepancies exist between actual patterns of care and recommendations based on clinical trials, according to a study of treatment patterns in adult patients with mantle cell lymphoma (MCL).
Age Associated With Survival, Time to Richter Transformation in AYA Patients With CLLMay 30th 2021
Age was associated with overall survival and the time to Richter transformation in adolescent and young adult patients with chronic lymphocytic leukemia, according to findings from a single-institutional, retrospective study.
FDA Approves Loncastuximab Tesirine for Relapsed/Refractory DLBCLApril 23rd 2021
The FDA has granted an accelerated approval to loncastuximab tesirine (Zynlonta) for the treatment of adult patients with relapsed/refractory large B-cell lymphoma following 2 or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low-grade lymphoma, and high-grade B-cell lymphoma.
Assessment Predicts Survival In Elderly Patients with DLBCLApril 2nd 2021
A simplified geriatric assessment offers a validated objective tool to assess fitness status and should be considered the new Elderly Prognostic Index standard to predict overall survival in older patients with diffuse large B-cell lymphoma.